News

Keros Therapeutics: Interesting Early Data From A Promising Molecule (Downgrade) (KROS)

3 Mins read

In April, I covered Keros Therapeutics, Inc. (NASDAQ:KROS), and found it interesting. Keros had three published datasets from three clinical-stage programs. The stock had a short rally after my coverage, then went down, took another small leap, and then went down

Response summary

RP2D Patients

All evaluable patients

HTB evaluable patients

Overall Erythroid Response (HI-E or TI) n (%)

19/37 (51.4)

11/22 (50)

IWG 2006 HI-E, n (%)

19/37 (51.4)

11/22 (50)

TI ≥8 weeks, n (%)

11/26 (42.3)

9/22 (40.9)

RS+, n (%)

8/19 (42.1)

6/17 (35.3)

Non-RS, n (%)

3/7 (42.9)

3/5 (60)

Read the full article here

Related posts
News

Supercharge SCHD ETF With Big Dividend Machines

1 Mins read
This article was written by Follow Samuel Smith has a diverse background that includes being lead analyst and Vice President at several…
News

KB Home (KBH) Q2 2025 Earnings Call Transcript

1 Mins read
KB Home (NYSE:KBH) Q2 2025 Earnings Conference Call June 23, 2025 5:00 PM ET Company Participants Jeffrey T. Mezger – Chairman &…
News

Advance Auto Parts Stock: Rally Is Not Supported By Fundamentals (NYSE:AAP)

1 Mins read
This article was written by Follow Over fifteen years of experience making contrarian bets based on my macro view and stock-specific turnaround…
Get The Latest News

Subscribe to get the top fintech and
finance news and updates.

Leave a Reply

Your email address will not be published. Required fields are marked *